Innoviva Price to Free Cash Flow Ratio 2010-2024 | INVA

Historical price to free cash flow ratio values for Innoviva (INVA) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Innoviva Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-11-01 19.26 9.94
2024-06-30 16.40 $1.94 8.46
2024-03-31 15.24 $1.77 8.60
2023-12-31 16.04 $1.62 9.91
2023-09-30 12.99 $1.35 9.60
2023-06-30 12.73 $1.24 10.26
2023-03-31 11.25 $1.36 8.29
2022-12-31 13.25 $2.12 6.26
2022-09-30 11.61 $2.62 4.43
2022-06-30 14.76 $4.03 3.66
2022-03-31 19.35 $4.16 4.65
2021-12-31 17.25 $3.86 4.47
2021-09-30 16.71 $4.00 4.18
2021-06-30 13.41 $3.08 4.35
2021-03-31 11.95 $2.85 4.19
2020-12-31 12.39 $2.76 4.49
2020-09-30 10.45 $2.60 4.03
2020-06-30 13.98 $2.45 5.72
2020-03-31 11.76 $2.24 5.25
2019-12-31 14.16 $2.27 6.24
2019-09-30 10.54 $2.22 4.74
2019-06-30 14.56 $2.25 6.47
2019-03-31 14.03 $2.21 6.36
2018-12-31 17.45 $1.97 8.85
2018-09-30 15.24 $1.83 8.35
2018-06-30 13.80 $1.66 8.31
2018-03-31 16.67 $1.39 11.98
2017-12-31 14.19 $1.18 12.00
2017-09-30 14.12 $0.95 14.84
2017-06-30 12.80 $0.75 17.01
2017-03-31 13.83 $0.66 20.98
2016-12-31 10.70 $0.49 21.72
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.205B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Merck (MRK) United States $258.042B 17.12
Novartis AG (NVS) Switzerland $223.511B 14.86
AstraZeneca (AZN) United Kingdom $221.444B 19.73
Pfizer (PFE) United States $159.177B 10.89
Sanofi (SNY) $135.190B 12.25